AU2013286177B2 - Use of long-acting GLP-1 peptides - Google Patents

Use of long-acting GLP-1 peptides Download PDF

Info

Publication number
AU2013286177B2
AU2013286177B2 AU2013286177A AU2013286177A AU2013286177B2 AU 2013286177 B2 AU2013286177 B2 AU 2013286177B2 AU 2013286177 A AU2013286177 A AU 2013286177A AU 2013286177 A AU2013286177 A AU 2013286177A AU 2013286177 B2 AU2013286177 B2 AU 2013286177B2
Authority
AU
Australia
Prior art keywords
glp
agonist
feature
misc
glu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2013286177A
Other languages
English (en)
Other versions
AU2013286177A1 (en
Inventor
Christine Bjorn Jensen
Peter Kristensen
Mads Frederik RASMUSSEN
Milan Zdravkovic
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Original Assignee
Novo Nordisk AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk AS filed Critical Novo Nordisk AS
Publication of AU2013286177A1 publication Critical patent/AU2013286177A1/en
Assigned to NOVO NORDISK A/S reassignment NOVO NORDISK A/S Amend patent request/document other than specification (104) Assignors: Christine Bjorn Jensen, MADS FREDERIK RASMUSSEN, MILAN ZDRAVKOVIC, NOVO NORDISK A/S, PETER KRISTENSEN
Priority to AU2018202504A priority Critical patent/AU2018202504B2/en
Application granted granted Critical
Publication of AU2013286177B2 publication Critical patent/AU2013286177B2/en
Priority to AU2020202573A priority patent/AU2020202573B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Child & Adolescent Psychology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
AU2013286177A 2012-07-01 2013-06-21 Use of long-acting GLP-1 peptides Active AU2013286177B2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2018202504A AU2018202504B2 (en) 2012-07-01 2018-04-10 Use of long-acting GLP-1 peptides
AU2020202573A AU2020202573B2 (en) 2012-07-01 2020-04-16 Use of long-acting GLP-1 peptides

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
EP12174535.0 2012-07-01
EP12174535 2012-07-01
US201261694837P 2012-08-30 2012-08-30
US61/694,837 2012-08-30
US201261708162P 2012-10-01 2012-10-01
EP12186781.6 2012-10-01
US61/708,162 2012-10-01
EP12186781 2012-10-01
PCT/EP2013/063004 WO2014005858A1 (en) 2012-07-01 2013-06-21 Use of long-acting glp-1 peptides

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2018202504A Division AU2018202504B2 (en) 2012-07-01 2018-04-10 Use of long-acting GLP-1 peptides

Publications (2)

Publication Number Publication Date
AU2013286177A1 AU2013286177A1 (en) 2015-01-15
AU2013286177B2 true AU2013286177B2 (en) 2018-04-26

Family

ID=65858459

Family Applications (3)

Application Number Title Priority Date Filing Date
AU2013286177A Active AU2013286177B2 (en) 2012-07-01 2013-06-21 Use of long-acting GLP-1 peptides
AU2018202504A Active AU2018202504B2 (en) 2012-07-01 2018-04-10 Use of long-acting GLP-1 peptides
AU2020202573A Active AU2020202573B2 (en) 2012-07-01 2020-04-16 Use of long-acting GLP-1 peptides

Family Applications After (2)

Application Number Title Priority Date Filing Date
AU2018202504A Active AU2018202504B2 (en) 2012-07-01 2018-04-10 Use of long-acting GLP-1 peptides
AU2020202573A Active AU2020202573B2 (en) 2012-07-01 2020-04-16 Use of long-acting GLP-1 peptides

Country Status (17)

Country Link
US (2) US9764003B2 (enExample)
EP (3) EP2866825B1 (enExample)
JP (1) JP6059802B2 (enExample)
AU (3) AU2013286177B2 (enExample)
BR (1) BR112014032938A2 (enExample)
CA (1) CA2877056A1 (enExample)
DK (1) DK2866825T3 (enExample)
ES (2) ES3041720T3 (enExample)
HR (2) HRP20251088T1 (enExample)
HU (2) HUE072859T2 (enExample)
MX (3) MX376058B (enExample)
PL (2) PL3689365T3 (enExample)
PT (1) PT2866825T (enExample)
RS (2) RS67258B1 (enExample)
RU (2) RU2018117557A (enExample)
SI (1) SI2866825T1 (enExample)
WO (1) WO2014005858A1 (enExample)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2651398T3 (pl) 2010-12-16 2018-05-30 Novo Nordisk A/S Stałe kompozycje zawierające agonistę GLP-1 i sól kwasu N-(8-(2-hydroksybenzoilo)amino)kaprylowego
DK2696687T3 (en) 2011-04-12 2017-02-06 Novo Nordisk As Double-acylated GLP-1 derivatives
EP4324475A1 (en) 2012-03-22 2024-02-21 Novo Nordisk A/S Compositions of glp-1 peptides and preparation thereof
JP6517690B2 (ja) 2012-06-20 2019-05-22 ノヴォ ノルディスク アー／エス ペプチド及び送達剤を含む錠剤製剤
RS67258B1 (sr) 2012-07-01 2025-10-31 Novo Nordisk As Upotreba dugodelujućih glp-1 peptida
KR20210086717A (ko) 2013-05-02 2021-07-08 노보 노르디스크 에이/에스 Glp-1 화합물의 경구 투여
CN110254223B (zh) * 2014-10-16 2022-03-25 洋马动力科技有限公司 拖拉机
GB201621987D0 (en) * 2016-12-22 2017-02-08 Archer Virgil L See Archer Sheri A Arecor Ltd Novel composition
DE102017106216A1 (de) * 2017-03-22 2018-09-27 Amw Gmbh Extrudierte Depotform zur anhaltenden Wirkstofffreisetzung
HUE066356T2 (hu) 2017-08-24 2024-07-28 Novo Nordisk As GLP-1 készítmények és alkalmazásaik
IL322969A (en) * 2017-10-12 2025-10-01 Novo Nordisk As Semaglutide in medical therapy
GB201720187D0 (en) * 2017-12-04 2018-01-17 Imperial Innovations Ltd Novel Compounds
WO2019149880A1 (en) 2018-02-02 2019-08-08 Novo Nordisk A/S Solid compositions comprising a glp-1 agonist, a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid and a lubricant
TWI705820B (zh) 2018-06-22 2020-10-01 美商美國禮來大藥廠 Gip/glp1促效劑組合物
WO2020028907A1 (en) * 2018-08-03 2020-02-06 Brown University Compositions and methods for improving the bioavailability of glp1 and analogues thereof
WO2020176678A1 (en) * 2019-02-26 2020-09-03 Twist Bioscience Corporation Variant nucleic acid libraries for glp1 receptor
EP3930757A1 (en) 2019-03-01 2022-01-05 President And Fellows Of Harvard College Methods and compositions for protein delivery
HRP20241052T1 (hr) * 2019-11-06 2024-11-08 Novo Nordisk A/S Semaglutid, namijenjen liječenju alzheimerove demencije
AU2020418207A1 (en) * 2019-12-30 2022-08-25 Gan & Lee Pharmaceuticals Co., Ltd. Long-acting GLP-1 compound
TW202140058A (zh) 2020-01-30 2021-11-01 美商美國禮來大藥廠 提派肽（ｔｉｒｚｅｐａｔｉｄｅ）之治療用途
WO2021162532A2 (ko) 2020-02-14 2021-08-19 주식회사 지투지바이오 Glp-1 유사체, 또는 이의 약학적으로 허용가능한 염을 포함하는 서방형 미립구를 포함하는 약학적 조성물
PE20221575A1 (es) * 2020-02-18 2022-10-06 Novo Nordisk As Formulaciones farmaceuticas
CN112768087A (zh) * 2020-12-23 2021-05-07 吉林大学 利用孟德尔随机化方法验证索马鲁肽口服制剂预防二型糖尿病的用途
JP2024527528A (ja) * 2021-06-24 2024-07-25 ギラ セラピューティクス インコーポレイテッド 満腹感を誘導する、及び代謝障害を治療するための方法及びキット
US12514908B2 (en) 2021-07-05 2026-01-06 Mapi Pharma Ltd. Semaglutide depot systems and use thereof
US11865213B2 (en) * 2021-07-05 2024-01-09 Mapi Pharma Ltd. Semaglutide depot systems and use thereof
FI4408840T3 (fi) 2021-09-27 2025-11-04 Terns Pharmaceuticals Inc Bentsimidatsolikarboksyylihappoja glp-1r-agonisteina
IL312364A (en) 2021-10-25 2024-06-01 Luehr Gary W Compounds as GLP-1R agonists
CA3237751A1 (en) 2021-11-10 2023-05-19 Tyler Brown Ionic liquid compositions
CN115850438B (zh) * 2021-12-28 2023-05-12 北京惠之衡生物科技有限公司 一种长效glp-1衍生物
US12410163B2 (en) 2022-02-23 2025-09-09 Terns Pharmaceuticals, Inc. Compounds as GLP-IR agonists
US20230374096A1 (en) * 2022-05-19 2023-11-23 Vault Bioventures, Inc. Obesity treatment and prevention methods
JP2026502943A (ja) 2022-12-30 2026-01-27 アルギファルマ エーエス 経口投与されるポリペプチド治療剤の全身バイオアベイラビリティを高める組成物および方法
WO2024211898A1 (en) 2023-04-07 2024-10-10 Terns Pharmaceuticals, Inc. Combination comprising a thrbeta agonist anda glp-1r agonist for use in treating a liver disorder or a cardiometabolic disease
CN121843690A (zh) 2023-07-24 2026-04-10 莱兰斯坦福初级大学评议会 用于递送治疗性肽的组合物和方法
KR102930984B1 (ko) * 2024-01-29 2026-02-25 주식회사 티온랩테라퓨틱스 세마글루타이드의 개선된 의료 요법 제공을 위한 비만 및 당뇨 치료용로써, 소수성 이온 페어링 겔레이션을 통한 초기 방출이 제어된 데포 조성물 및 이의 제조방법
WO2025165146A1 (ko) * 2024-01-29 2025-08-07 주식회사 티온랩테라퓨틱스 세마글루타이드 또는 티르제파타이드의 개선된 의료 요법 제공을 위한 비만 및 당뇨 치료용으로써, 소수성 이온 페어링 겔레이션을 통한 초기 방출이 제어된 데포 조성물 및 이의 제조방법
WO2026046328A1 (en) * 2024-08-30 2026-03-05 Beijing Ql Biopharmaceutical Co., Ltd. Dosing regimen of glp-1 conjugates
CN118845644B (zh) * 2024-09-27 2025-01-17 杭州信海医药科技有限公司 一种司美格鲁肽注射液的制备方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010092163A2 (en) * 2009-02-13 2010-08-19 Boehringer Ingelheim International Gmbh Antidiabetic medications
WO2011138421A1 (en) * 2010-05-05 2011-11-10 Boehringer Ingelheim International Gmbh Combination therapy

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK39892D0 (da) 1992-03-25 1992-03-25 Bernard Thorens Peptid
JP3149958B2 (ja) 1996-08-30 2001-03-26 ノボ ノルディスク アクティーゼルスカブ Ｇｌｐ―１誘導体
US20030119734A1 (en) 2001-06-28 2003-06-26 Flink James M. Stable formulation of modified GLP-1
KR101241862B1 (ko) 2003-09-19 2013-03-13 노보 노르디스크 에이/에스 신규 ｇｌｐ-1 유도체
PT1687019T (pt) 2003-11-20 2018-02-26 Novo Nordisk As Formulações de péptidos que contêm polietileno glicol que são ótimas para produção e para utilização em dispositivos de injeção
EP2494983B1 (en) 2004-11-12 2019-04-24 Novo Nordisk A/S Stable formulations of glp-1
TWI372629B (en) 2005-03-18 2012-09-21 Novo Nordisk As Acylated glp-1 compounds
WO2007121411A2 (en) 2006-04-14 2007-10-25 Mannkind Corporation Glucagon-like peptide 1(glp-1) pharmaceutical formulations
US20100047762A1 (en) 2007-03-20 2010-02-25 Nippon Kayaku Kabushiki Kaisha Method to monitor drug efficacy in diabetic patients using an assay for 1,5-anhydro-d-glucitol
US20110144010A1 (en) 2007-06-01 2011-06-16 Novo Nordisk A/S Spontaneously Dispersible Preconcentrates Including a Peptide Drug in a Solid or Semisolid Carrier
WO2009030774A1 (en) 2007-09-05 2009-03-12 Novo Nordisk A/S Truncated glp-1 derivatives and their therapeutical use
ES2672770T3 (es) 2007-09-05 2018-06-18 Novo Nordisk A/S Derivados del péptido-1 similar al glucagón y su uso farmacéutico
US20100317057A1 (en) 2007-12-28 2010-12-16 Novo Nordisk A/S Semi-recombinant preparation of glp-1 analogues
DK2373681T3 (en) 2008-12-10 2017-04-24 Glaxosmithkline Llc PHARMACEUTICAL COMPOSITIONS OF ALBIGLUTID
CA2784757A1 (en) * 2009-12-16 2011-07-07 Novo Nordisk A/S Double-acylated glp-1 derivatives
WO2012016419A1 (zh) 2010-08-06 2012-02-09 浙江贝达药业有限公司 Glp-1衍生物及其应用
PL2651398T3 (pl) * 2010-12-16 2018-05-30 Novo Nordisk A/S Stałe kompozycje zawierające agonistę GLP-1 i sól kwasu N-(8-(2-hydroksybenzoilo)amino)kaprylowego
US20130035281A1 (en) * 2011-02-09 2013-02-07 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
CN102718858B (zh) 2011-03-29 2014-07-02 天津药物研究院 胰高血糖素样肽-1类似物单体、二聚体及其制备方法与应用
WO2012136790A1 (en) 2011-04-07 2012-10-11 Glaxo Group Limited Compositions comprising fusion proteins or conjugates with an improved half -life
CN102229668A (zh) 2011-06-03 2011-11-02 浙江贝达药业有限公司 一种glp-1衍生物及其应用
WO2012177929A2 (en) * 2011-06-24 2012-12-27 Amylin Pharmaceuticals, Inc. Methods for treating diabetes with extended release formulations of glp-1 receptor agonists
RS67258B1 (sr) 2012-07-01 2025-10-31 Novo Nordisk As Upotreba dugodelujućih glp-1 peptida

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010092163A2 (en) * 2009-02-13 2010-08-19 Boehringer Ingelheim International Gmbh Antidiabetic medications
WO2011138421A1 (en) * 2010-05-05 2011-11-10 Boehringer Ingelheim International Gmbh Combination therapy

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Clinical Trial NCT00696657, entitled "A Randomised Controlled Clinical Trial in Type 2 Diabetes Comparing Semaglutide to Placebo and Liraglutide," pp. 1-5 (3/11/2015) at URL clinicaltrials.gov/archive/NCT00696657/2011_03_25 *
S. MADSBAD ET AL, "An overview of once-weekly glucagon-like peptide-1 receptor agonists-available efficacy and safety data and perspectives for the future", DIABETES, OBESITY AND METABOLISM, (20110324), vol. 13, no. 5, pages 394 - 407 *

Also Published As

Publication number Publication date
AU2020202573A1 (en) 2020-05-07
WO2014005858A1 (en) 2014-01-09
CA2877056A1 (en) 2014-01-09
EP3689365B1 (en) 2025-08-06
JP6059802B2 (ja) 2017-01-11
PL3689365T3 (pl) 2025-11-12
AU2018202504B2 (en) 2020-05-07
PT2866825T (pt) 2020-07-15
SI2866825T1 (sl) 2020-07-31
RU2657573C2 (ru) 2018-06-14
EP4406593A2 (en) 2024-07-31
DK2866825T3 (da) 2020-06-08
JP2015522573A (ja) 2015-08-06
PL2866825T3 (pl) 2021-02-22
EP2866825B1 (en) 2020-04-08
RS67258B1 (sr) 2025-10-31
EP3689365A1 (en) 2020-08-05
MX2014014946A (es) 2015-04-08
BR112014032938A2 (pt) 2017-08-01
AU2018202504A1 (en) 2018-05-10
AU2020202573B2 (en) 2023-04-20
MX366405B (es) 2019-07-08
MX2020010693A (es) 2020-11-06
ES3041720T3 (en) 2025-11-14
RS60432B1 (sr) 2020-07-31
ES2796839T3 (es) 2020-11-30
HUE072859T2 (hu) 2025-12-28
RU2015101826A (ru) 2016-08-20
MX376058B (es) 2025-03-07
MX2019008148A (es) 2019-09-05
EP3689365C0 (en) 2025-08-06
US9764003B2 (en) 2017-09-19
US20150190474A1 (en) 2015-07-09
US10335462B2 (en) 2019-07-02
AU2013286177A1 (en) 2015-01-15
HUE049152T2 (hu) 2020-09-28
US20180085435A1 (en) 2018-03-29
RU2018117557A3 (enExample) 2021-08-20
HRP20200889T1 (hr) 2020-09-04
HRP20251088T1 (hr) 2025-11-07
EP2866825A1 (en) 2015-05-06
RU2018117557A (ru) 2019-03-22
EP4406593A3 (en) 2024-10-23

Similar Documents

Publication Publication Date Title
AU2020202573B2 (en) Use of long-acting GLP-1 peptides
AU2012311484B2 (en) Novel glucagon analogues
US20200392197A1 (en) Antibody peptide conjugates that have agonist activity at both the glucagon and glucagon-like peptide 1 receptors
US20160136246A1 (en) Novel Uses of GLP-1 Receptor Agonists in Patients Treated with Insulin and/or Suffering from Type 1 Diabetes
US11274135B2 (en) Double-acylated GLP-1 derivatives
KR20190045393A (ko) 이중 아실화된 ｇｌｐ-1 유도체

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)